15 stories mentioning SHE:000661
Every FINWIRES story that references SHE:000661, newest first.
China's drug regulator approved production of GenSci136 for injection produced by Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Jinsai Pharmaceutical.The drug is indicated for ocular myasthenia gravis, a condition that affects the movement of the muscles controlling eye movements and eyelids.
Changchun High-Tech Industry (SHE:000661) subsidiary GeneScience obtained China's regulatory approval to conduct clinical trials for GenSci155 injection.The drug is indicated for preventing bronchopulmonary dysplasia in premature infants and treating acute ischemic stroke, according to a Thursday filing with the Shenzhen bourse.Shares of the drug manufacturer closed 2% lower Thursday.
Changchun High-Tech Industry (SHE:000661) subsidiary GeneScience received the approval of the U.S. Food and Drug Administration to start clinical trials in the U.S. for GenSci136.The drug is indicated for autoimmune disease myasthenia gravis, according to a Tuesday filing with the Shenzhen bourse.Shares of the drug manufacturer closed 2% lower Tuesday.
Changchun High-Tech Industry (SHE:000661) subsidiary GeneScience received approval of the U.S. Food and Drug Administration to start clinical trials in the U.S. for GenSci145 tablets.The drug is indicated for locally advanced or metastatic solid tumors with PIK3CA mutations, which occur in 30% to 40% of breast cancers, according to a Tuesday filing with the Shenzhen bourse.Shares of the drug manufacturer closed 2% lower Tuesday.
Changchun High-Tech Industry's (SHE:000661) subsidiary, Changchun GeneScience Pharmaceutical, received approval from China's National Medical Products Administration for the clinical trials of GenSci144 tablets, according to a Shenzhen bourse filing on Wednesday.The drug will be tested as a treatment for phenylketonuria, a genetic disorder caused by defects in the phenylalanine hydroxylase gene, leading to hyperphenylalaninemia.The Chinese drug manufacturer's shares dropped 2% during the afternoon trade.
China's drug regulator accepted Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Jinsai Pharmaceutical's clinical trial application for its GenSci144 tablets for chronic kidney disease, according to a Tuesday filing with the Shenzhen bourse.
Changchun High-Tech Industry (SHE:000661) unit Genescience obtained the U.S. Food and Drug Administration's approval to conduct clinical trials for GenSci161 injection.The drug is used to treat hidradenitis suppurativa, a chronic inflammatory skin disease, according to a weekend filing with the Shenzhen bourse.Shares of the drug manufacturer closed 2% lower Monday.
Changchun High-Tech Industry (SHE:000661) secured Chinese regulatory approval to begin clinical trials for fuxinqibai injection.The monoclonal antibody is indicated for reducing acute gout flares during early urate-lowering therapy, according to a Wednesday filing with the Shenzhen bourse.Shares of the drug manufacturer were down 2% in recent trade.
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory acceptance for the clinical trial application of GenSci155 injection.The drug is indicated to prevent bronchopulmonary dysplasia in preterm infants and to treat acute ischemic stroke, according to a Thursday filing with the Shenzhen bourse.
Changchun High-Tech Industry's (SHE:000661) attributable profit fell 42% to 275.7 million yuan in the first quarter from 472.7 million yuan in the year-ago period, according to a Wednesday filing with the Shenzhen bourse.Earnings per share at the drug manufacturer decreased to 0.69 yuan from 1.17 yuan in the prior-year period.Operating income declined 14% year over year to 2.59 billion yuan from 3 billion yuan.
Changchun High-Tech Industry's (SHE:000661) attributable profit fell 94% to 155 million yuan in 2025 from 2.58 billion yuan in 2024, according to a Wednesday filing with the Shenzhen bourse.Earnings per share at the drug manufacturer decreased 94% to 0.39 yuan from 6.42 yuan in the previous year.Operating income declined 10% year over year to 12.1 billion yuan from 13.5 billion yuan.
China's drug regulator approved Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Jinsai Pharmaceutical's clinical trial for its GS3-007a dry suspension, according to a Friday filing with the Shenzhen bourse.The drug promotes growth hormone secretion, helping treat idiopathic short stature, the filing said.
China's drug regulator approved Changchun High-Tech Industry's (SHE:000661) clinical trial of its GenSci136 injection, according to a Friday filing with the Shenzhen bourse.The injection is indicated for generalized myasthenia gravis, an acquired autoimmune condition characterized by impaired neuromuscular junction transmission, the filing said.It affects muscle groups and impacts chewing, swallowing, raising arms, combing hair, and climbing stairs, among other actions.
Changchun High-Tech Industry (SHE:000661) unit Jinsai Pharmaceutical received China's regulatory approval to conduct clinical trials for vuxin qibai monoclonal antibody injection, according to a Wednesday filing with the Shenzhen bourse.The drug targets non-infectious uveitis, an eye inflammation.